Skip to content
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Menu
Search
Toggle Menu
Change Country
Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Initiatives
Our Company
Our COVID-19 Efforts
The Road to a Vaccine
About J&J
Our Credo
Our Leadership Team
Living Our Values
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
J&J Health and Wellness Solutions
Veterans, Military & Military Families
Products
Consumer Health
Medical Devices
Pharmaceutical Products
Procurement
Value Pillars
Supplier Diversity
Supplier Standards
Careers
What We Do
How We Hire
Job Spotlight
Employee Benefits
Students
Innovation
Career Stories
Media Center
Investors
2021 Annual Shareholders Meeting
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2020 Janssen Transparency Report
2020 Health for Humanity Report
ESG Investor Update
ESG Resources
Stock Information
Webcasts & Presentations
Investor Fact Sheet
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Sustainability
Follow Us
Facebook
facebook
Instagram
instagram
LinkedIn
linkedin
Twitter
twitter
YouTube
youtube
Close Countries Menu
Explore more Johnson & Johnson sites:
Australia
alt
Argentina
alt
Brazil
alt
Canada
alt
Chile
alt
China
alt
Colombia
alt
Costa Rica
alt
Czech Republic
Ecuador
alt
Germany
alt
India
alt
Japan
alt
Mexico
alt
New Zealand / Pacific
alt
Paraguay
alt
Peru
alt
Philippines
alt
Russia
alt
Switzerland
alt
German
English
French
United Kingdom
alt
United States
alt
Uruguay
alt
Venezuela
alt
Close Search Menu
Search input
Johnson & Johnson Announces Plans to Separate Consumer Health Business
Learn More
Share
Investor Information
Johnson & Johnson to Host Business Review Highlighting Pharmaceuticals
Johnson & Johnson to Host Business Review Highlighting Pharmaceuticals
Register
Listen to Webcast: Johnson & Johnson Analyst Call
Listen to Webcast: Credit Suisse 30th Annual Healthcare Conference
Listen to Webcast: Investor Conference Call on Third-Quarter Results
NYSE: JNJ
$162.28
-$1.00 (
-0.610
%)
Day High
$164.47
Day Low
$162.13
Volume
3,665,169
Last Updated:
11/18/2021 02.26 PM
Latest News Releases
Our Company
November 12, 2021
Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business
October 21, 2021
U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines
October 20, 2021
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
See All News Releases
Webcast: 2020 Medical Devices Update
Webcast: 2020 Medical Devices Update
ON NOW
Webcast: 2020 Medical Devices Update
2020 Health for Humanity Report
2020 Health for Humanity Report
ON NOW
2020 Health for Humanity Report
2020 Janssen U.S. Transparency Report
2020 Janssen U.S. Transparency Report
ON NOW
2020 Janssen U.S. Transparency Report
2020 Annual Report
2020 Annual Report
ON NOW
alt
2020 Annual Report
Investor Relations
Corporate Governance
Corporate Governance
ON NOW
alt
Corporate Governance
SEC Filings
SEC Filings
ON NOW
SEC Filings
Pharmaceutical Pipeline
Pharmaceutical Pipeline
ON NOW
Pharmaceutical Pipeline
Stock Information
Stock Information
ON NOW
Stock Information
Webcasts & Presentations
Webcasts & Presentations
ON NOW
Webcasts & Presentations
Investor Fact Sheet
Investor Fact Sheet
ON NOW
Investor Fact Sheet
Quarterly Results
See the latest quarterly sales and earnings from Johnson & Johnson, as well as historical results covering the past ten years.
Learn More
Shareholder Tools
Email Alerts Subscription
RSS News Feeds
Investor FAQs
Answers to common questions regarding purchasing and owning Johnson & Johnson stock.
Learn More
ESG Resources
Effective management of ESG matters is a business imperative.
Learn More
Contact Investor Relations
Questions? Please contact Investor Relations:
1-800-950-5089
Learn more about our Guidelines for Communication with the Investment Community (Reg FD)
This site uses cookies as described in our
Cookie Policy
Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Accept
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue